Key Takeaways
- Aclarion’s Nociscan technology has been recognized as a finalist in the 2025 Digital Health Awards for its innovative approach to diagnosing chronic low back pain.
- Nociscan is the first evidence-supported SaaS platform that helps distinguish between painful and non-painful lumbar discs using magnetic resonance spectroscopy.
- This nomination highlights Aclarion’s commitment to improving healthcare efficiency and support for millions suffering from chronic low back pain.
Aclarion’s Nociscan Finalist for 2025 Digital Health Awards
Aclarion, Inc. has been named a finalist in the Rising Star – Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation: Digital Health Awards. This recognition underscores the company’s efforts to position Nociscan as the standard for identifying sources of chronic low back pain, affecting an estimated 266 million people globally.
The Nociscan platform is the first evidence-supported software-as-a-service (SaaS) solution that noninvasively assists physicians in differentiating between painful and non-painful discs in the lumbar spine. It employs magnetic resonance spectroscopy (MRS) to convert MR signals into objective biomarkers linked to disc pain. This capability enables healthcare providers to devise more personalized treatment plans for patients.
Brent Ness, CEO of Aclarion, expressed honor at the recognition and emphasized its validation of the company’s innovation and vision. Being chosen from over 1,800 submissions illustrates Aclarion’s dedication to bringing meaningful change to the healthcare sector.
The Digital Health Hub Foundation’s awards celebrate advancements in digital healthcare that improve speed, efficiency, and equity. Aclarion’s inclusion as a finalist reflects its commitment to enhancing diagnostic processes for chronic low back pain while contributing to broader healthcare improvements.
Aclarion uses sophisticated algorithms to analyze the MRS data received from MRI machines. This cloud-based approach allows for quantification of chemical biomarkers indicative of disc pain. The insights derived from Nociscan provide physicians with essential data to optimize treatment strategies, aligning with the growing need for innovative solutions in chronic pain management.
For more details on locating a Nociscan center or information about the technology, interested parties are encouraged to visit Aclarion’s official website.
Professionals and stakeholders are also invited to reach out via the provided contact email for inquiries about the technology and its applications in clinical settings.
The content above is a summary. For more details, see the source article.
